natgillin/translations-raw huggingface dataset:
Pakningsstørrelser og yderligere oplysninger Rixathon indeholder: 
Contents of the pack and other information What Rixathon contains
Rixathon 100 mg koncentrat til infusionsvæske, opløsning EU/1/17/1185/001 
Rixathon 100 mg concentrate for solution for infusion EU/1/17/1185/001
Gennemsnitlig clearance og fordelingsvolumen for rituximab var henholdsvis 0,313 l/dag (0,116-0,726 l/dag) og 4,50 l (2,25-7,39 l). 
Rituximab mean clearance and volume of distribution were 0.313 L/day (range, 0.116 - 0.726 L/day) and 4.50 L (range 2.25 - 7.39 L) respectively.
Efterfølgende Rixathon-doser kan infunderes med 100 mg/time initialt og øges med 100 mg/time hvert 30. minut til højst 400 mg/time. 
Subsequent doses of Rixathon can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h.
Placebo+MTX Rituximab+MTX 2 × 1.000 mg 
Placebo+MTX Rituximab+MTX 2 x 1,000 mg
Patientkortet for Rixathon indeholder følgende nøgle-elementer: - Nødvendigheden af altid at have kortet på sig og at vise kortet til alt behandlende sundhedspersonale - Advarsel om risikoen for infektioner og PML, inklusive alle symptomer - Nødvendigheden af, at patienterne kontakter deres læge, hvis de får symptomer 
The Patient Alert Card for Rixathon contains the following key elements: - The need to carry the card at all times and to show the card to all treating health care professionals - Warning on the risk of infections and PML, including the symptoms - The need for patients to contact their health care professional if symptoms occur
Kemisk og fysisk stabilitet af Rixathon, der er fortyndet i 5 % glukoseopløsning, er blevet påvist i 24 timer ved 2 °C - 8 °C og efterfølgende 12 timer ved stuetemperatur (≤25 °C). 
Chemical and physical stability of Rixathon diluted in 5% glucose solution has been demonstrated for 24 hours at 2°C - 8°C and subsequently 12 hours at room temperature (≤25°C).
• Hvis du får Rixathon sammen med kemoterapi 
• If you are having Rixathon with chemotherapy
Andelen af patienter behandlet med rituximab, som viste minimal klinisk relevant ændring (MCID) i HAQ-DI (defineret som et fald i individuel total score på > 0,22) var også højere end hos patienter, som fik methotrexat alene (tabel 14). 
The proportions of rituximab treated patients showing a minimal clinically important difference (MCID) in HAQ-DI (defined as an individual total score decrease of > 0.22) was also higher than among patients receiving methotrexate alone (Table 14).
I alt 117 patienter (88 med GPA, 24 med MPA og 5 med nyre-begrænset antineutrofil cytoplasmisk antistof (ANCA)-associeret vaskulitis) i sygdomsremission blev randomiseret til at få henholdsvis azathioprin (59 patienter) eller rituximab (58 patienter) i et prospektiv, kontrolleret, åbent multicenterstudie. 
A total of 117 patients (88 with GPA, 24 with MPA, and 5 with renal-limited ANCA-associated vasculitis) in disease remission were randomized to receive azathioprine (59 patients) or rituximab (58 patients) in a prospective, multi-center, controlled, open-label study.
Hos patienter med reumatoid artrit sås øjeblikkelig B-celle depletering i perifert blod efter to infusioner af 1.000 mg rituximab med 14 dages interval. 
In rheumatoid arthritis patients, immediate depletion of B cells in the peripheral blood was observed following two infusions of 1,000 mg rituximab separated by a 14 day interval.
Blymfocytter er medvirkende til nogle af de symptomer, du har. 
B lymphocytes are involved in the cause of some of the symptoms you have.
I et prospektivt, ublindet, internationalt, multicenter fase III-studie fik 1.193 patienter med tidligere ubehandlet, fremskredent follikulært lymfom induktionsbehandling med R-CHOP (n=881), R-CVP (n=268) eller R-FCM (n=44) efter investigators valg. 
In a prospective, open label, international, multi-centre, phase III trial 1,193 patients with previously untreated advanced follicular lymphoma received induction therapy with R-CHOP (n=881), R-CVP (n=268) or R-FCM (n=44), according to the investigators' choice.
Signifikant reduktion i funktionsindeks (HAQ-DI) og træthedsscore (FACIT-Fatigue) blev observeret hos patienter, der blev behandlet med rituximab, sammenlignet med patienter behandlet med methotrexat alene. 
Significant reductions in disability index (HAQ-DI) and fatigue (FACIT-Fatigue) scores were observed in patients treated with rituximab compared to patients treated with methotrexate alone.
Rixathon 500 mg koncentrat til infusionsvæske, opløsning EU/1/17/1185/003 
Rixathon 500 mg concentrate for solution for infusion EU/1/17/1185/003
Tabel 8 Induktionsfase: Oversigt over effektdata for CHOP versus R-CHOP (31 måneders median observationstid) 
Table 8 Induction phase: overview of efficacy results for CHOP vs. R-CHOP (31 months median observation time)
Studier af tidligere ubehandlet og relaps/refraktær CLL har fastslået, at hos op til 25 % af patienterne behandlet med R-FC var neutropeni forlænget (defineret som neutrofiltal, der forblev under 1 x 109/l mellem dag 24 og 42 efter sidste dosis) eller indtraf sent (defineret som neutrofiltal under 1 x 109/l senere end dag 42 efter sidste dosis hos patienter uden tidligere forlænget neutropeni eller hos patienter, som restituerede før dag 42) efter behandling med rituximab plus FC. 
Studies in previously untreated and relapsed/refractory CLL have established that in up to 25% of patients treated with R-FC neutropenia was prolonged (defined as neutrophil count remaining below 1 x 109/L between day 24 and 42 after the last dose) or occurred with a late onset (defined as neutrophil count below 1 x 109/L later than 42 days after last dose in patients with no previous prolonged neutropenia or who recovered prior to day 42) following treatment with rituximab plus FC.
Forskellen i den samlede overlevelse viste en stærk klinisk forskel (p=0,029, log rank test stratificeret ved center): overlevelsesrater på 53 måneder var 80,9 % for patienter i R-CVP-gruppen i forhold til 71,1 % for patienter i CVP-gruppen. 
The difference between the treatment groups with respect to overall survival showed a significant clinical difference (p=0.029, log-rank test stratified by centre): survival rates at 53 months were 80.9% for patients in the R-CVP group compared to 71.1% for patients in the CVP group.
De bivirkninger, der opsummeres i tabel 5, forekom alle med en hyppighed ≥ 5 % blandt rituximab-behandlede patienter med PV med en ≥ 2 % absolut forskel i forekomst mellem den rituximab-behandlede gruppe og standarddosis prednison-gruppen op til måned 24. 
Adverse drug reactions presented in Table 5 were adverse events which occurred at a rate of ≥ 5% among rituximab-treated PV patients, with a ≥ 2% absolute difference in incidence between the rituximab-treated group and the standard-dose prednisone group up to month 24.
• angst, depression 
• Anxiety, depression
I det kliniske studie med induktion af remission havde henholdsvis 27 %, 58 % og 51 % af patienterne i rituximab-gruppen med normale immunglobulin-niveauer ved baseline lave IgA-, IgG- og IgMniveauer ved måned 6 sammenlignet med henholdsvis 25 %, 50 % og 46 % i cyclophosphamidgruppen. 
In the induction of remission clinical trial, at 6 months, in the rituximab group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline, had low IgA, IgG and IgM levels, respectively compared to 25%, 50% and 46% in the cyclophosphamide group.
Det anbefales, at immunglobulinniveauer måles før initiering af Rixathon-behandling. 
It is recommended that immunoglobulin levels are determined prior to initiating treatment with Rixathon.
Kemisk og fysisk stabilitet af Rixathon, der er fortyndet i 0,9 % natriumchloridopløsning, er blevet påvist i 30 dage ved 2 °C - 8 °C og efterfølgende 24 timer ved stuetemperatur (≤25 °C). 
Chemical and physical stability of Rixathon diluted in 0.9% sodium chloride solution has been demonstrated for 30 days at 2°C - 8°C and subsequently 24 hours at room temperature (≤25°C).
Rixathon er indiceret til behandling af tidligere ubehandlede patienter med stadium III-IV follikulært lymfom i kombination med kemoterapi. 
Rixathon is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Under anvendelse af aseptiske procedurer trækkes den nødvendige mængde Rixathon op og fortyndes til en beregnet koncentration på 1 til 4 mg/ml rituximab i en infusionspose, der indeholder steril, pyrogenfri natriumchloridopløsning til injektion 9 mg/ml (0,9 %) eller 5 % D-glukose i vand. 
Aseptically withdraw the necessary amount of Rixathon, and dilute to a calculated concentration of 1 to 4 mg/mL rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/mL (0.9%) solution for injection or 5% D-Glucose in water.
Af de 99 patienter, der blev behandlet med rituximab, oplevede 12 (12 %) mindst én infusionsrelateret reaktion. 
Of the ninety nine patients treated with rituximab, 12 (12%) experienced at least one IRR.
lungeinfiltrater 
Lung infiltration
Placebo+MTX Rituximab+MTX (2 × 1.000 mg) 
Placebo+MTX Rituximab+MTX (2 x 1,000 mg)
Tabel 5 Bivirkninger opstået hos rituximab-behandlede patienter med pemfigus vulgaris i det kliniske studie op til måned 24 
Table 5 Adverse drugs reactions for rituximab-treated pemphigus vulgaris patients in the clinical study up to month 24
I alt 19 ud af 34 (56 %) patienter med PV, som blev behandlet med rituximab, blev testet positive for ADA antistoffer ved måned 18. 
A total of 19/34 (56%) patients with PV, who were treated with rituximab, tested positive for ADA antibodies by 18 months.
4 Herunder observationer, som var indsamlet som en del af rutinemæssig laboratorie-overvågning 5 Inklusive dødelige tilfælde 
4 Includes observations collected as part of routine laboratory monitoring.
Rixathon bør ikke administreres til patienter med en aktiv, alvorlig infektion (for eksempel tuberkulose, sepsis og opportunistiske infektioner, se pkt. 
Rixathon should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3).
Den samlede responsrate i intent-to-treat populationen var 48 % (95 % konfidensinterval: 41 %-56 %) med 6 % komplet respons (CR) og 42 % partielt respons (PR). 
The overall response rate (ORR) in the intent-to-treat (ITT) population was 48% (CI95% 41%-56%) with a 6% complete response (CR) and a 42% partial response (PR) rate.
Antallet af patienter behandlet med rituximab plus lavdosis prednison uden prednison-behandling eller behandlet minimalt (prednison dosis på 10 mg eller mindre pr. dag) viser en steroidbesparende virkning af rituximab sammenlignet med patienter behandlet med standarddosis prednison over behandlingsperioden på 24 måneder (figur 4). 
The number of rituximab plus low-dose prednisone patients off prednisone therapy or on minimal therapy (prednisone dose of 10 mg or less per day) compared to standard-dose prednisone patients over the 24-month treatment period shows a steroid-sparing effect of rituximab (Figure 4).
I relaps/refraktær-studiet var medianen for progressionsfri overlevelse (det primære endepunkt) 30,6 måneder i R-FC-gruppen og 20,6 måneder i FC-gruppen (p=0,0002, log-rank test). 
In the relapsed/refractory study, the median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group (p=0.0002, log-rank test).
Rituximab kan føre til svimmelhed og kan påvirke din evne til at køre motorkøretøj eller arbejde med maskiner. 
Rituximab may make you feel dizzy and may affect your ability to drive or use any tools or machines.
Ligeledes blev et godt til moderat European League Against Rheumatism (EULAR) respons i alle studier opnået af signifikant flere patienter behandlet med rituximab og methotrexat sammenlignet med patienter behandlet med methotrexat alene (tabel 12). 
Similarly, a good to moderate European League Against Rheumatism (EULAR) response was achieved by significantly more rituximab treated patients treated with rituximab and methotrexate compared to patients treated with methotrexate alone (Table 12).
Der er kun begrænsede effekt-og sikkerhedsdata tilgængelige for patienter, som tidligere er behandlet med monoklonale antistoffer inklusive rituximab, og for patienter, som er refraktære over for tidligere behandling med rituximab og kemoterapi. 
Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.
Samlet respons rate * chi-i-anden-test p-værdi odds ratio (95 % KI) Komplet respons (CR/CRu) rate* chi-i-anden-test p-værdi odds ratio (95 % KI) 
Overall response rate* chi-squared test p value odds ratio (95% CI) Complete response (CR/CRu) rate* chi-squared test p value odds ratio (95% CI)
Tabel 10b Førstelinjebehandling af kronisk lymfatisk leukæmi Hazard ratioer for progressionsfri overlevelse efter Binet stadium (ITT) - median observationstid: 48,1 måneder 
Table 10b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT)48.1 months median observation time
• smerte ved vandladning (urinvejsinfektion) 
• Pain on passing water (urinary tract infection)
Effekt og sikkerhed af rituximab til lindring af symptomer og kliniske fund ved reumatoid artrit hos patienter med et utilstrækkelig respons på TNF-hæmmere blev vist i et pivotalt, randomiseret, kontrolleret, dobbeltblindet, multicenterstudie (studie 1). 
The efficacy and safety of rituximab in alleviating the symptoms and signs of rheumatoid arthritis in patients with an inadequate response to TNF-inhibitors was demonstrated in a pivotal randomised, controlled, double-blind, multicenter trial (Trial 1).
Sikkerhed og effekt af rituximab er ikke påvist i kombination med andre kemoterapiregimer til behandling af diffust storcellet B-celle non-Hodgkin-lymfom. 
Safety and efficacy of rituximab have not been established in combination with other chemotherapies in diffuse large B cell non- Hodgkin's lymphoma.
almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til ≤ 1/100) og meget sjælden (< 1/10.000). 
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and very rare (< 1/10,000).
I det kliniske studie med induktion af remission, som inkluderede 99 rituximab-behandlede patienter var den samlede infektionshyppighed ca. 237 pr. 100 patientår (95 % konfidensinterval 197-285) ved det primære endepunkt ved måned 6. 
In the clinical trial on induction of remission, which included 99 rituximab-treated patients, the overall rate of infection was approximately 237 per 100 patient years (95% CI 197 - 285) at the 6-month primary endpoint.
Rixathon kan passere moderkagen og påvirke barnet. 
This is because Rixathon can cross the placenta and may affect your baby.
Fortæl lægen, apotekspersonalet eller sundhedspersonalet om al medicin, du tager i øjeblikket, har taget for nyligt eller planlægger at tage. 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Rixathon gives altid i et drop (intravenøs infusion). 
You will always be given Rixathon as a drip (intra-venous infusion).
I en subgruppeanalyse var den samlede responsrate højere hos patienter med histologisk subtype IWF B, C og D sammenlignet med subtype IWF A (58 % versus 12 %), højere hos patienter hvis største læsions længste diameter var < 5 cm versus > 7 cm (53 % versus 38 %) og højere hos patienter med kemoterapifølsomt relaps sammenlignet med kemoterapiresistent relaps (defineret som en responsvarighed < 3 måneder) (50 % versus 22 %). 
In a subgroup analysis, the ORR was higher in patients with IWF B, C, and D histological subtypes as compared to IWF A subtype (58% vs. 12%), higher in patients whose largest lesion was < 5 cm vs. > 7 cm in greatest diameter (53% vs. 38%), and higher in patients with chemosensitive relapse as compared to chemoresistant (defined as duration of response < 3 months) relapse (50% vs. 22%).
Rituximabs sikkerhedsprofil ved non-Hodgkin-lymfom og CLL er baseret på data fra patienter fra kliniske studier og fra post-marketing overvågning. 
The overall safety profile of rituximab in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia is based on data from patients from clinical trials and from post-marketing surveillance.
Granulomatose med polyangiitis og mikroskopisk polyangiitis Rixathon er i kombination med glukokortikoider indiceret til behandling af voksne patienter med svær, aktiv granulomatose med polyangiitis (Wegeners granulomatose) (GPA) eller mikroskopisk polyangiitis (MPA). 
Granulomatosis with polyangiitis and microscopic polyangiitis Rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).
Rituximabs binding til CD 20 antigenet på B-lymfocytter har vist også at inducere celledød via apoptose. 
Rituximab binding to CD 20 antigen on B lymphocytes has also been demonstrated to induce cell death via apoptosis.
Medicin, der gives inden hver behandling med Rixathon 
Medicines given before each Rixathon administration
Tabel 17 Fuldstændig remission ved måned 6 opgjort efter sygdomsstatus Rituximab Cyclophosphamid 
Table 17 Complete remission at 6-months by disease status Rituximab Cyclophosphamide Difference (CI 95%)
Rixathon vedligeholdelsesbehandling er indiceret til behandling af follikulært lymfom hos patienter, der responderer på induktionsbehandling. 
Rixathon maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Den mediane responsvarighed var 37,7 måneder i R-CVP-gruppen, og den var 13,5 måneder i CVPgruppen (p < 0,0001), log rank test). 
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 0.0001, log-rank test).
Samtidig/fortløbende anvendelse af andre DMARDs hos patienter med reumatoid artrit Samtidig anvendelse af Rixathon og andre antireumatiske behandlinger, end dem der er specificeret under reumatoid artrit-indikation og dosering, anbefales ikke. 
Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of Rixathon and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Den endelige analyse bekræftede, at R-CHOP behandlingen var forbundet med klinisk relevant og statistisk signifikant forbedring af længden af den progressionsfrie overlevelse (de primære effektparametre var død, relaps, forværring af lymfomet eller påbegyndelse af ny antilymfombehandling) (p=0,0001). 
The final analysis confirmed that R-CHOP treatment was associated with a clinically relevant and statistically significant improvement in the duration of event-free survival (the primary efficacy parameter; where events were death, relapse or progression of lymphoma, or institution of a new anti-lymphoma treatment) (p=0.0001).
Derfor bør patienter med hjertelidelse og/eller tidligere kardiotoksisk kemoterapi i anamnesen monitoreres nøje. 
Therefore patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely.
Rixathon er en klar, farveløs til let gullig opløsning, leveret som koncentrat til infusionsvæske, opløsning. 
Rixathon is a clear, colourless to slightly yellowish solution, supplied as a concentrate for solution for infusion.
Den tilberedte Rixathon-opløsning skal gives som en intravenøs infusion gennem en separat anlagt intravenøs adgang. 
The prepared Rixathon solution should be administered as an intravenous infusion through a dedicated line.
I et prospektivt, ublindet, internationalt, multicenter fase III-studie, blev 465 patienter med recidiveret/ refraktært follikulært lymfom i første omgang randomiseret til induktionsbehandling med enten CHOP (cyclophosphamid, doxorubicin, vincristin, prednisolon; n=231) eller rituximab plus CHOP (R-CHOP, n=234). 
In a prospective, open label, international, multi-centre, phase III trial, 465 patients with relapsed/refractory follicular lymphoma were randomised in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) or rituximab plus CHOP (R-CHOP, n=234).
Tabel 11 Behandling af relapsed/refraktær kronisk lymfatisk leukæmi - sammenfatning af resultaterne for effekt for rituximab plus FC versus FC alene (median observationstid: 25,3 måneder) 
Table 11 Treatment of relapsed/refractory chronic lymphocytic leukaemia - overview of efficacy results for rituximab plus FC vs. FC alone (25.3 months median observation time)
Lægemidler til behandling af hypersensitivitetsreaktioner, for eksempel epinephrin (adrenalin), antihistaminer og glukokortikoider, bør være tilgængelige til øjeblikkelig anvendelse, i tilfælde af en allergisk reaktion under administration af Rixathon. 
Medicinal products for the treatment of hypersensitivity reactions, e.g. epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of Rixathon.
I CLL 1. linjestudiet oplevede Binet C patienter i R-FC-armen flere bivirkninger sammenlignet med patienter i FC-armen (R-FC 83 % versus FC 71 %). 
In the CLL first-line study, Binet stage C patients experienced more adverse events in the R-FC arm compared to the FC arm (R-FC 83% vs. FC
Hvis du er i tvivl, skal du kontakte lægen, apotekspersonalet eller sundhedspersonalet, inden du får Rixathon. 
If you are not sure, talk to your doctor, pharmacist or nurse before you are given Rixathon.
Granulomatose med polyangiitis og mikroskopisk polyangiitis Patienter behandlet med Rixathon skal have udleveret patientkortet ved hver infusion. 
Granulomatosis with polyangiitis and microscopic polyangiitis Patients treated with Rixathon must be given the patient alert card with each infusion.
Natriumcitrat, polysorbat 80, natriumchlorid, natriumhydroxid, saltsyre, vand til injektionsvæsker. 
Sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections.
Du kan have behov for ekstra overvågning under din behandling med Rixathon. 
Your doctor may need to take special care of you during your treatment with Rixathon.
e) Hvis du behandles for pemfigus vulgaris 
e) If you are being treated for pemphigus vulgaris
Hvis en sådan bivirkning skulle opstå med formodet relation til Rixathon, skal behandlingen seponeres permanent. 
In case of such an event with a suspected relationship to Rixathon, treatment should be permanently discontinued.
1 hætteglas indeholder 10 mg/ml rituximab. 
1 vial contains 10 mg/mL rituximab.
Det skal du vide, før du begynder at få Rixathon Du må ikke få Rixathon, hvis 
What you need to know before you are given Rixathon Do not take Rixathon if
Hepatitis B-reaktivering 
Hepatitis-B reactivation
• Rixathon gives samme dag som kemoterapien. 
• Rixathon will be given to you on the same day as your chemotherapy.
Rixathon skal administreres som to 500 mg intravenøse infusioner, med to ugers mellemrum, efterfulgt af en 500 mg intravenøs infusion hver 6. måned. 
Rixathon should be administered as two 500 mg IV infusions separated by two weeks, followed by a 500 mg IV infusion every 6 months thereafter.
Baseret på den farmakokinetiske populationsanalyse af data fra 97 patienter med GPA eller MPA, der fik 375 mg/m2 rituximab én gang ugentligt i 4 uger, var den estimerede mediane terminale halveringstid 23 dage (9-49 dage). 
Based on the population pharmacokinetic analysis of data in 97 patients with granulomatosis with polyangiitis and microscopic polyangiitis who received 375 mg/m2 rituximab once weekly for four doses, the estimated median terminal elimination half-life was 23 days (range, 9 - 49 days).
Nervesystemet paræstesi, hypoæstesi, agitation, insomni, vasodilatation, svimmelhed, angst 
Paraesthesia, hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety